Today we announced interim data from HELIOS, our ongoing Phase 2 #clinicaltrial studying the treatment of #Wolframsyndrome . The interim analysis demonstrated that our investigational therapy had a clinically meaningful effect on key outcomes measuring the progression of diabetes,…

Join us for a webcast this Wednesday, April 10, to discuss interim data from HELIOS, a Phase 2 #clinicaltrial studying the treatment of #Wolframsyndrome . Amylyx management is excited to present these data alongside Dr. Fumi Urano MD PhD - Wolfram Doc, Principal Investigator of the HELIOS clinical…

Today we shared an update on our next steps, including a process we’ve initiated to remove our ALS treatment from the market and provide free access to therapy for those who wish to stay on. These decisions were informed by people who will be impacted and engagement with…

Today we announced the newest member of our Board of Directors, Bernhardt Zeiher. Dr. Zeiher joins us at a pivotal time and brings more than 20 years of experience in the #pharma industry with expertise in drug development. Welcome, Bernie! bit.ly/3ID1NqA

Today, we shared the topline results from our Phase 3 PHOENIX trial. Read more in our press release: bit.ly/3TbILMC

On behalf of the entire Amylyx team, we are grateful to the ALS community and for the dedication of trial participants, investigators, and study site…

Today is #RareDiseaseDay . On average, it can take a person living with a rare disease 5 years to receive a diagnosis. For people living with ALS, early diagnosis can mean more time with loved ones. Visit TogetherForALS.com to learn more. #ColorMeRare #TogetherForALS

On #RareDiseaseDay , we stand together to raise awareness for those living with #neurodegenerativediseases like #ALS , #PSP , and #WolframSyndrome . Our commitment is driven by our pursuit of innovative therapies and our mission to one day end the suffering caused by these diseases.

February 29th is #RareDiseaseDay . Rare diseases affect 3-6% of the global population, including 200,000 people who are living with motor neuron diseases such as ALS. Amylyx is dedicated to bringing people with rare diseases together. #ColorMeRare #TogetherForALS

CENTAUR remains the first and only to show both the slowing of disease progression and extending overall survival in a single #ALS trial. See how we are building on learnings from that trial to move forward.

We’re excited to share that we’ll be presenting two abstracts at the Muscular Dystrophy Association (@MDAOrg) Clinical and Scientific Conference, taking place March 3-6 in Orlando. Learn more about our poster presentations: bit.ly/49xz1TF #MDAconference

Today we announced we’ve completed enrollment of HELIOS, our Phase 2 #clinicaltrial studying the treatment of #Wolframsyndrome (WS). Thank you to all those who partnered with us on this important milestone. Learn more: bit.ly/3SAEmmn

Join us on Feb 21 for our second Amylyx Aktuell HCP webinar, as part of our series on #neurodegenerative diseases. Experts in #neuromuscular diseases Prof. Dr. Dorst and Dr. Boentert will discuss practical aspects of ventilation for #PLWALS .

eur.cvent.me/QAKP1?RefId=X

#DYK it takes about a year for those living with #ALS to receive a diagnosis? Because of this, it’s important to track any possible symptoms. See the most common symptoms below.

Progressive supranuclear palsy ( #PSP ) is a rare
#neurodegenerative disease that progressively
affects brain cells that control balance,
coordination, eye movement, speech, swallowing,
and thinking. Learn about the symptoms below.

We’re committed to our mission in ending the suffering caused by #neurodegenerative diseases like #ALS . Whether you're a person living with ALS, a friend, or family member, visit our resource page for support and community. bit.ly/3RrzuR8

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.